MD Anderson investigators will lead patient enrollment, sample collection, clinical data analysis and manuscript writing. Myriad will provide funding, MRD testing and scientific research support ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback